Clinical trial · Interventional
To Evaluate Transoral Flexible Endoscope With Narrow Band Imaging in Nasopharyngeal Cancer
A Pilot Study to Evaluate the Use of a Transoral Flexible Endoscope With Magnifying Narrow Band Imaging in Nasopharyngeal Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Nasopharyngeal carcinoma (NPC) is endemic in our region and is the 9th most common cancer in Hong Kong. Traditionally diagnosis has been through a nasoendoscopic examination of the nasopharynx with white light followed by a biopsy of suspicious lesions for a confirmatory diagnosis. However, given the geometry of the anatomy of the nasopharynx, with its inherent crevices and varying amounts of lymphoid tissues, lesions are not always easily identified leading to potential missed lesions. The non-specific aspect of white light also leads to excessive biopsies that are not without risk and of some discomfort to patients. Recent advances in liquid biopsies have also allowed for the detection of earlier and smaller lesions that are not always easily identified on nasoendoscopy but rather are seen on Magnetic Resonance Imaging (MRI)1 . An alternative imaging technique is the use of Narrow Band Imaging (NBI) to view the vasculature of the mucosa to identify suspicious lesions for pre-malignancy and malignancy that has been popularized in the gastrointestinal tract. In NPC, NBI with the flexible nasoendoscopes has been used in the diagnosis of NPC with varying success2-5 . Our own group's research has found that in NPC NBI has limitations arising from a lack of consensus on vascular findings on NBI that constitute malignancy, lack of magnification and long focal length of current nasoendoscopes5-8 . Flexible endoscopy using conventional esophago-gastroscopy endoscope (OGD) with NBI and magnification power up to 80x overcome the limitations of current nasoendoscopes, however their size precludes the passing of these endoscopes through the nasal cavity. Here in this pilot study we will seek to use an OGD with NBI passed transorally and retroflexed into the nasopharynx to view the nasopharynx with increased magnification and clarity to evaluate the feasibility of this study in the diagnosis of nasopharyngeal carcinoma. Study questions: 1. Is it feasible to use an OGD with magnifying NBI for the diagnosis of NPC? 2. Are there features detected on NBI OGD that are diagnostic of NPC? 3. Do histological features correspond with NBI findings?
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Nasopharyngeal Carcinoma | Nasopharyngeal Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| transoral flexible endoscope with magnifying narrow band imaging | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- esophago-gastroscopy endoscopy with narrow band imaging
- description
- a transoral flexible endoscope with magnifying narrow band imaging in nasopharyngeal examination
- interventionNames
- Device: transoral flexible endoscope with magnifying narrow band imaging
Primary outcomes (1)
- measure
- The vasculature of the nasopharyngeal region
- timeFrame
- during enrollment period
- description
- The vasculature of the nasopharyngeal region which capture by the transoral flexible endoscope with magnifying narrow band imaging
Secondary outcomes (1)
- measure
- Histological features of nasopharyngeal lesion
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
General Inclusion Criteria for both study groups, Test group and Control group. 1. No previous radiotherapy to the head and neck region 2. 18 Years and older 3. Able to provide informed consent 4. No cognitive impairment Test group - Specific Inclusion Criteria 1) Newly diagnosed primary nasopharyngeal carcinoma Control group - Specific Inclusion Criteria 1\) Patients undergoing an OGD for lesions not involving disease of the head and neck region General Exclusion Criteria for both study groups, Test group and Control group. 1. On anticoagulation including Plavix, warfarin and NOAC's 2. Current mucosal lesions of the head and neck region 3. History of malignancy 4. Concomitant malignant disease 5. Trismus preventing an OGD
References
Publications (0)
Data not yet available